All In Biotech

Free tool

FAERS Monitor: Joenja

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217759 or its brand name (Joenja, Leniolisib Phosphate). Reports on generic versions are filed under their own applications.

Reports

937

Serious

177

19% of reports

Hospitalization

80

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infection153
  • product dose omission issue133
  • off label use67
  • sinusitis63
  • headache47
  • nasopharyngitis44
  • fatigue32
  • ear infection29
  • pneumonia29
  • diarrhoea27
  • nausea24
  • alopecia23
  • upper respiratory tract infection22
  • cough21
  • influenza19

Reports by year received

View as table
YearReports
20181
20221
2023128
2024222
2025290
2026295

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,222 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ear infectionSignal2924.517.1630
infectionSignal15323.820.53,331
sinusitisSignal6313.810.9739
upper respiratory tract infectionSignal2210.77.1184
product dose omission issueSignal13310.28.71,104
nasopharyngitisSignal445.44.0153
influenzaSignal193.82.537
alopeciaSignal232.61.822
pneumoniaSignal292.01.414
off label use671.71.420
headache471.71.313
cough211.71.15
diarrhoea270.90.60
fatigue320.90.70
nausea240.70.53

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.